I stumbled upon another ongoing trial lead by Paul Ridker. This one is the Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) trial. Pemafibrate (aka K-877) is a selective peroxisome proliferator activator receptor-alpha (PPAR-alpha) modulator and will be tested in high-risk diabetic patients with high triglyceride and low HDL-C levels who are already taking statins. PPAR-alpha is a transcription factor, thus a small molecule like K-877 is modulating the activity of PPAR-alpha and this is turn will affect the transcription of genes under control of PPAR-alpha. 

PROMINENT is another trial to keep an eye on. Still early in the game with read out not expected until 2022. But similar to BETonMACE it is looking at a diabetes, low-HDL population. Furthermore, two of the PPAR-alpha target genes are apo-AI and ABCA1; so PPAR-alpha activation leads to increased HDL levels in humans in a way that increases functional HDL. However, many, many other genes are also regulated by PPAR-alpha, so this is not an HDL selective drug. No relation to the CETP story. 

Landmark Trial Entitled "PROMINENT" To Explore The Prevention Of Heart Disease In Diabetic Patients With High Triglycerides And Low HDL-C